Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15246 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Simeon I Taylor und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glycosuria, Symporters. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Aim
To validate pharmacodynamic responses to sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and test for association with genetic variants in SLC5A4 , SLC5A9 , and SLC2A9 .
Methods
Canagliflozin (300 mg), a SGLT2 inhibitor, was administered to 30 healthy volunteers. Several endpoints were measured to assess clinically relevant responses, including drug‐induced increases in urinary excretion of glucose, sodium and uric acid.
Results
This pilot study confirmed that canagliflozin (300 mg) triggered acute changes in mean levels of several biomarkers: fasting plasma glucose (−4.1 mg/dL; P = 6 × 10 −5 ), serum creatinine (+0.05 mg/dL; P = 8 × 10 −4 ) and serum uric acid (−0.90 mg/dL; P = 5 × 10 −10 ). The effects of sex on glucosuria depended upon how data were normalized. Whereas males' responses were ~60% greater when data were normalized to body surface area, males and females exhibited similar responses when glucosuria was expressed as grams of urinary glucose per gram‐creatinine. The magnitude of glucosuria was not significantly correlated with fasting plasma glucose, estimated glomerular filtration rate or age in those healthy individuals without diabetes with an estimated glomerular filtration rate of more than 60 mL/min/1.73m 2 .
Conclusions
Normalizing data relative to creatinine excretion will facilitate including data from males and females in a single analysis. Furthermore, because our ongoing pharmacogenomic study (NCT02891954) is conducted in healthy individuals, this will facilitate detection of genetic associations with limited confounding by other factors such as HbA1c and renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA.
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
ORCID-Profile: Simeon I Taylor
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Taylor, S. I., Cherng, H. R., Shahidzadeh Yazdi, Z., Montasser, M. E., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Streeten, E. A., & Beitelshees, A. L. (2023). Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15246
Vancouver
Taylor SI, Cherng HR, Shahidzadeh Yazdi Z, Montasser ME, Whitlatch HB, Mitchell BD, et al. Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15246
BibTeX
@article{Taylor2023,
author = {Taylor, Simeon I and Cherng, Hua-Ren and Shahidzadeh Yazdi, Zhinous and Montasser, May E and Whitlatch, Hilary B and Mitchell, Braxton D and Shuldiner, Alan R and Streeten, Elizabeth A and Beitelshees, Amber L},
title = {Pharmacogenetics of sodium‐glucose co‐transporter‐2 inhibitors: Validation of a sex‐agnostic pharmacodynamic biomarker},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15246}
}
EUVIMED